Predictors of long-term remission in patients with Crohn's disease treated with adalimumab
Not Applicable
Recruiting
- Conditions
- Crohn's disease
- Registration Number
- JPRN-UMIN000010856
- Lead Sponsor
- Graduate School of Medicine, Chiba University, Department of Gastroenterology and Nephrology (K1)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Contraindication for adalimumab (2) Previous use of adalimumab (3) Less than 15 years old (4) Women who are pregnant or breastfeeding (5) Less than 6 months after surgery (6) Patients with short bowel syndrome (7) Patients with malignancy (8) Patients who are considered unsuitable in the opinion of the investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical remission rates (evaluated by CDAI) at 52 weeks of adalimumab treatment.
- Secondary Outcome Measures
Name Time Method